DOCSLIB.ORG

Directory of North Carolina Manufacturing Firms

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Directory of North Carolina Manufacturing Firms 7 PRODUCT GUIDE SIC 2824-2841 SYNTHON TEXTILE INC SCHERER. R P CORP S E GOODYS MFG CORP (WELLCOME FOUNDATION LTD INC 26 Glendale Avenue Biltmore P Box 847 P Box 10518 Salem Station Burroughs Wellcome Co IE Asheville 28803 Monroe 281 10 Winston Salem 27108 PO Box 1887 Buncombe County Emp. C Union County Emp. F Forsyth County Emp. E Greenville 27834 " Phone: (704)253-8453 Phone: (704)289-5451 Phone: (919)723-1831 Pitt County Emp I Polyester fibers Nutritional supplements Headache powders Phone: (919)758-3436 Drugs Veterinary products GREER LABORATORIES INC E WHITAKER. FRED I CO Drugs & chemicals (packaged) P Box 27506 STANBACK CO P Box 800 Lenoir 28645 Raleigh 27611 Box 1669 2841 SOAP AND OTHER DETERGENTS Salisbury 28144 Caldwell County Emp. F Wake County Emp E EXCEPT SPECIALTY CLEANERS Phone: (919)832-8383 Rowan County Emp. E Phone: (704)754-5327 Synthetic fibers Phone: (704)633-9231 Allergenic extract ACME SOUTHERN INC Breath freshner HORNE HEALTH CARE P Box 1 1264 2831 BIOLOGICAL PRODUCTS Chap et lip balm P Box 206 Charlotte 28220 Headache powders Everetts 2 7825 Mecklenburg County Emp. D AMERICAN LABORATORY SUPPLY INC Martin County Emp D Phone: (704)523-1452 P Box 1096 WINTON PRODUCTS CO INC E Phone: (919)792-4135 Various textile specialties Burlington 27215 P Box 36332 Cough syrups & antihistamines Alamance County Emp C Charlotte 28236 ADVANCED CHEMICAL TECHNOLOGY INC Phone: (919)229-5865 Mecklenburg County Emp. B tMALLINCKRODT INC 2151 Hawkins St Prepared microbiological cultures Phone: (704)399-5151 Parenteral Plant IE Charlotte 28203 Rodent repellent PO Box 61038 Mecklenburg County Emp. C t BAYER AG Raleigh 27661 Phone: (704)375-0055 Cutter Laboratories Inc ZEMA CORPORATION E Wake County Emp. F Soaps & detergents P Box 507 P Box 12803 Phone: (919)878-2900 Clayton 27520 Research Triangle Park 27709 AEROCHEM CORP Parenteral products Johnston County Emp G Wake County Emp. C P O Box 2330 Phone: (919)851-9494 INC Phone: (919)553-501 1 MAYRAND High Point 27261 Plasma fraction Pet products P Box 8869 Guilford County Emp. D Greensboro 27419 Phone (919)889-1000 BIOLOGICAL SUPPLY 2834 'CAROLINA CO PHARMACEUTICAL PREPARATIONS Guilford County Emp. D Maintenance chemicals Granite Diagnostics Inc Phone (919)292-5347 ABBOTT LABORATORIES INC Rt 1 Box 1 1 0-S Pharmaceuticals APOLLO CHEMICAL CORP PO Box 2226 1 Southerland i Warrenton 27589 105 St Rocky Mount 27801 (MERCK & COMPANY Warren County Emp B Graham 27253 Nash Emp. 1 Merck Sharp & Dohme Div Phore: (919)456-2326 County Alamance County Emp D 1 1 Route Box Processed blood Phone: (919)977-51 2 558 Phone: (919)226-1 161 Wilson / v solutions small volume 27893 Textile fabric detergents t GRANITE TECHNOLOGICAL ENTERPRISES 1 v solutions large volume Wilson County Emp. D Granite Diagnostics Inc E Phone (919)243-201 1 BARJO INCORPORATED INC ' AG MARK P Box 908 Pharmaceuticals P Box 21643 P Box 1 2 7 Greensboro 27420 : Burlington 27215 Teachey 28464 t MILES LABORATORIES INC Alamance County Emp D Guilford County Emp B Duplin County Emp. C Cutter Laboratories Inc Phone (919)226-631 1 Phone (919)274-9691 Phone: (919)285-2144 P Box 507 Animal blood products Heavy duty cleaner Drug premixes Clayton 27520 Prepared microbiological media Vitamins Johnston County Emp. E BURLINGTON INDUSTRIES E Processed blood products j Animal health products Phone: (919)553-501 1 P O Drawer 939 GREER LABORATORIES INC E Intravenous solution Intralipid Jamestown 27282 1 AJINOMOTO INC P Box 800 Guilford County Emp. F Ajinomoto U S A Inc E t NATIONAL STARCH & CHEM CO Lenoir 28645 Phone: (919)454-314 1 4020 Ajinomoto Dr Leland Plant IE Caldwell County Emp. F Soap & detergents non household I Raleigh 27610 PO Box 130 Phone:(704)754-5327 Wake County Emp F Leland 28451 CAROCHEM INC Sterile vaccines Brunswick County Emp. D Phone: (919)832-2890 P Box 1 1247 Phone HAPPY JACK INC Ammo acids for food products (919)371-2234 Durham 27703 Animal biologies PO Box 475 Ammo acids for pharmaceuticals Durham County Emp. C Vetmanan pharmaceutics Snow Hill 28580 Phone: (919)596-0678 t BAXTER-TRAVENOL LABORATORIES INC 1 Greene County Emp. C PHARMACONTROL CORP Soaps-detergents-cleaners Travenol Laboratories Inc E Phone:4919)747-3572 East Main & Stone Streets P Box 1390 tCHEM CLEAN INC Milkaoz Pilot Mountain 27041 Marion 28752 Bright Supply Co Surry County Emp. D PO Box 1555 2833 MEDICINAL CHEMICALS AND McDowell County Emp J 1 Phone. Not available Phone: (704)756-4151 Gastonia 28052 BOTANICAL PRODUCTS Soluble aspirin Intravenous solutions Gaston County Emp C t PRILLAMAN CO Phone: (704)864-0327 AQUA 10 CORP E Z MIX ANIMAL NUTRITION INC Daly-Herring Co Inc Sanitary supplies and chemicals Beaufort 28516 P Box P P Box 428 Carteret County Emp E Wendell 27591 CLOROX CO, THE Phone: Kmston 28501 (919)728-2270 Wake County Emp B 800 Gesco Street Lenior County Emp. D Extract chemicals seaweed Phone: (919)365-4957 Charlotte 28208 Phone: (919)527-8001 Vitamin & mineral animal premixes Mecklenburg County Emp D t BAYER AG Pet products Phone: (704)333-7733 Cutter Laboratories Inc t ESMARK INC Spray adjuvants Soap & detergents P Box 507 Almay Inc t RICHARDSON VICKS INC Clayton 27520 P Box 748 FINETEX INC Vicks Health Care Division Johnston County Emp. G Apex 27502 P Box 1 64 PO Box 22086 Phone: (919)553-501 1 Wake County Emp G Spencer 28159 Greensboro 27420 Hospital product sets Phone: (919)362-7422 Rowan County Guilford County Emp. G Pharmaceuticals Phone- (704)633-8028 BRISTOL-MYERS CO E Phone (919)292-2420 Liquid soap P O Box 300 FINETEX INC Proprietary pharmaceuticals Mornsville 27560 P Box 1 64 KAY CHEMICAL CO t SQUIBB. E R & SONS Wake County Emp. G Spencer 28159 P Box 18407 Squibb. E R & Sons Inc I Phone: (919)467-3500 Rowan County P Box 1000 Greensboro 2 7419 Pharmaceuticals Phone: (704)633-8028 Kenly 27542 Guilford County Emp E Pharmaceutical products Phone: (919)292-7713 HAPPY JACK INC Johnston County Emp. F Phone. Chemical cleaners P Box 475 t GLAXO HOLDINGS (919)284-5131 Industrial detergents Snow Hill 28580 Glaxo Inc Mfg & pkg penicillin Greene County Emp. C P Box 13398 SURRY CHEMICALS INC ROYAL CHEMICAL CO Phone: (919)747-3572 Research Triangle Park 27709 PO Box 144 7 Box 922 Skin balm Durham County Emp H Mount Airy 27030 Albemarle 28001 Flea powder Phone (919)248-2100 Surry County Emp, B Stanly County Emp C Worm capsules Pharmaceutical products Phone: (919)786-4607 Phone: (704)982-5513 Mange medicine Pool supplies (chemicals) Cleaning compounds t GLAXO HOLDINGS MOFFITT. C J MEDICINE CO INC Glaxo Inc VIKON CHEMICAL CO INC TRANSEASTERN CORP 103 Whittier Ave P O Box 1 2 1 P Box 1520 P Box 756 High Point 27260 Zebulon 27597 Burlington 27215 Wilson 27893 Guilford County Emp. D Wake County Alamance County Emp. B Wilson County Emp, E Phone: (919)886-4964 Phone: (919)269-6738 Phone (919)226-6331 Phone: (919)237-3107 Patent medicine Pharmaceuticals Bactericides & fungicides Detergent Employment: 1-4, 5-9, 10-19, A B C D 20-49, E 50-99, F 100-249, I G 250-499, H 500-999, 1000-2499, J 2500+ / t Parent Company E Export I Import "Purchase D-95.
Load more

Recommended publications
  • Cholesterol How Kos Beat Big Pharma to HDL
    The Other Cholesterol How Kos Beat Big Pharma to HDL www.pharmexec.com | ANADVANSTAR★ PUBLICATION Kos CEO Adrian Adams PHARMACEUTICAL EXECUTIVE Contents OCTOBER 2004 www.pharmexec.com Cover Story Under Construction Patrick Clinton Editor-in-Chief How Kos Pharmaceuticals turned a 50-year-old drug for raising HDL cholesterol into a brand-new, burgeoning business. Mulling the Future Kos CEO Adrian Adams, seated, maps strategy with key executives: (from left) Ralf Rosskamp, Christopher Kiritsy, Richard King, and Mark McGovern “We didn’t start with the idea of being a $200 million company. Growing as fast as possible: That was our goal from the get-go.” Kos Pharmaceuticals was first to market with a product to raise HDL cholesterol, and it wants to join pharma’s billion-dollar club by 2007. Big plan. Under Here’s how it’s going. Construction t’s hard to imagine that many pharma companies experienced more plain old good news this summer than Kos Pharmaceuticals. First, there were the second-quarter financials. Revenues for the quarter were $120.3 million, almost double last year’s figure. Net income for the quarter grew 245 percent to $38.5 million. The company raised its guidance for the year, predicting that full-year sales would be $480 million, 60 percent over last year— and CEO Adrian Adams boasted that Kos was the fastest-growing specialty pharma company in the United States. A few weeks later came encouraging results from a Phase II trial of IKos’ new inhalable insulin product for diabetes, and recruitment began for pivotal trials of a new combination product to consolidate Kos’ position in the burgeoning cholesterol market.
    [Show full text]
  • Board of Director Candidates
    2021 Annual General Meeting Board of Director Candidates James I. Healy, M.D., Ph.D. (Current Board Member) James I. Healy, M.D., Ph.D. has served as a member of our board of directors since November 2014. Dr. Healy has been a General Partner of Sofinnova Investments, Inc. (formerly Sofinnova Ventures), a venture capital firm, since June 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories) and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the board of directors of Bolt Therapeutics, Inc. (Nasdaq: BOLT), Coherus BioSciences, Inc. (Nasdaq: CHRS), Karuna Therapeutics, Inc. (Nasdaq: KRTX), Natera, Inc. (Nasdaq: NTRA), NuCana plc (Nasdaq: NCNA), ObsEva SA (Nasdaq: OBSV) and Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) and two private companies. Previously, he served as a board member of Amarin Corporation, Auris Medical Holding AG, Edge Therapeutics, Inc., Hyperion Therapeutics, Inc., InterMune, Inc., Iterum Therapeutics PLC, Anthera Pharmaceuticals, Inc., Durata Therapeutics, Inc., CoTherix, Inc., Movetis NV and several private companies. Dr. Healy holds an M.D. and a Ph.D. in Immunology from Stanford University School of Medicine and holds a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from the University of California, Berkeley. Jan Møller Mikkelsen (Current Board Member) Jan Møller Mikkelsen founded Ascendis Pharma and has served as President and Chief Executive Officer as well as Board member since December 2007 and currently serves on the board of Visen. From 2002 to 2006, Mr. Mikkelsen served as President and Chief Executive Officer of LifeCycle Pharma A/S, now Veloxis Pharmaceuticals A/S, which was a publicly traded biotechnology company.
    [Show full text]
  • Medication Precautions
    MEDICATION PRECAUTIONS If you want to be pro-active to decrease bruising during injection treatments such as Restylane, Botox and Mesotherapy; the following prescriptions and non-prescription medications may be discontinued for at least two weeks prior to having any injection procedure to ensure that your platelets have time to recover. These specific preparations have been found to affect your blood by decreasing the amount of time it takes for coagulation and decreasing the amount of red blood cell production which can lead to increased bruising. If you are taking any antiarthritics or anticoagulants for control of a medical disorder, you will need to consult your treating physician for recommendations as to the alternatives. If you must take these medications, appropriate determinations as to whether they may be a detriment during the procedure may be discussed. NONPRESCRIPTION MEDICATIONS • Aspirin combinations • Alka-Seltzer Effervescent Antacid & Pain Reliever (Miles Laboratories) • Alka-Seltzer (Flavored) Effervescent Antacid & Pain Reliever (Miles Laboratories) • Alka-Seltzer Extra Strength Effervescent Antacid & Pain Reliever (Miles Laboratories) • Anacin Analgesic Coated Caplets (Whitehall) • Anacin Analgesic Coated Tablets (Whitehall) • Anacin Maximum Strength Coated Analgesic Tablets (Whitehall) • Arthritis Pain Formula by the Makers of Anacin Analgesic Tablets and Caplets (Whitehall) • Arthritis Strength BC Powder (Block) • Ascriptin Tablets (Rorer) • Ascriptin A/D Tablets (Rorer) • Bayer Children’s Chewable Aspirin (Glenbrook)
    [Show full text]
  • Editorial Board L
    EDITORIAL BOARD L. LEON CAMPBELL, Editor-in-Chief University ofIllinois, Urbana L. S. BARON, Editor (1969) L. JOE BERRY, Editor (1968) Ifalter Reed Army Institute ofResearch, Washington, D.C. Bryn Mawr College, Bryn Mawr, Pa. R. D. DeMOSS, Editor (1970) University ofIllinois, Urbana R. L. Anderson (1969) Herman Friedman (1969) Robert C. Parlett (1969) Robert Austian (1969) Lorraine Friedman (1968) Harry D. Peck (1970) W. Lane Barksdale (1969) Ruth E. Gordon (1969) Michael J. Pelczar, Jr. (1969) S. S. Barkulis (1969) Joseph S. Gots (1969) H. J. Phaff (1969) Alan W. Berheimer (1969) Leonard Hayflick (1969) Roy Repaske (1969) Robert W. Bernlohr (1970) James G. Hirsch (1969) H. V. Rickenberg (1970) S. Gaylen Bradley (1969) John G. Holt (1969) C. F. Robinow (1969) Arnold F. Brodie (1970) Paul Howard-Flanders (1969) W. R. Romig (1969) Allan Campbell (1969) Jerard Hurwitz (1969) NM R. J. Salton (1969) George B. Chapman (1969) Arthur G. Johnson (1969) Russell W. Schaedler (1969) V. P. Cirillo (1970) Elliot Juni (1967) W. R. Sistrom (1969) A. J. Clark (1969) R. E. Kallio (1969) Louis DS. Smith (1968) V. W. Cochrane (1969) Carl Lamanna (1970) Paul F. Smith (1970) S. F. Conti (1969) Maurice Landy (1970) Roger Y. Stanier (1970) C. D. Cox (1969) H. S. Levinson (1969) M. P. Starr (1970) William J. Cromartie (1969) H. C. Lichstein (1970) B. A. D. Stocker (1969) Roy Curtiss m (1969) W. R. Lockhart (1969) Bernard S. Strauss (1969) A. L. Demain (1969) Donald G. Lundgren (1968) Curtis B. Thorne (1969) Eliznbe McCoy (1969) John A. DeMoss (1969) H.
    [Show full text]
  • Biogen Idec Inc. (Exact Name of Registrant As Specified in Its Charter)
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2003 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-19311 Biogen Idec Inc. (Exact name of registrant as specified in its charter) Delaware 33-0112644 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 14 Cambridge Center, Cambridge, Massachusetts 02142 (Address of principal executive offices) (Zip code) (617) 679-2000 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: None Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.0005 par value Series X Junior Participating Preferred Stock Purchase Rights (Title of class) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No o Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • Alternatives to Animal Use in Research, Testing, and Education
    Appendix Laboratory-Animal Facilities Fully Accredited by the American Association for Accreditation of Laboratory Animal Care As of April 1, 1985, there were 483 facilities listed Michigan: as fully accredited by the American Association for University of Michigan, Ann Arbor, Dearborn, Accreditation of Laboratory Animal Care (AAALAC) and Flint (New Lenox, IL). Institutions are categorized as univer- Wayne State University, Detroit sities, medical schools, combined facilities for health Missouri: sciences, veterinary schools, dental schools, colleges University of Missouri-Kansas City, Kansas City of pharmacy, colleges of biological science, colleges of Montana: arts, colleges of engineering, Veterans’ Administration University of Montana, Missoula medical centers, pharmaceutical manufacturers, gov- Nebraska: ernment laboratories, commercial laboratories, hos- University of Nebraska at Omaha, Omaha pitals, nonprofit research laboratories, or laboratory New York: animal breeders. The following list of AAALAC-accred- St. John’s University, Jamaica ited facilities numbers 538, as some institutions are State University of New York at Buffalo, Buffalo listed in more than one category. (Facilities receiving Rockefeller University, New York accreditation since April 1, 1985, are not listed.) North Carolina: Duke University, Durham Oklahoma: Universities Oral Roberts University, Tulsa (Programs serving an entire campus) Rhode Island: Brown University, Providence Alabama: South Carolina: University of Alabama, University University of South Carolina,
    [Show full text]
  • Robert J. Desalvo Papers Business Combinations in the Cosmetic and Pharmaceutical Industries 1944
    Robert J. DeSalvo Papers Business Combinations in the Cosmetic and Pharmaceutical Industries 1944 - 1990 Collection #107 Abstract Robert J. DeSalvo’s research focused on business combinations (acquisitions, mergers, and joint ventures in the cosmetic and pharmaceutical industries. This topic was the basis for his master’s thesis in pharmacy administration at the University of Pittsburgh and continued as a life-long interest. This collection consists of two series of notebooks that Dr. DeSalvo developed to record relevant business combinations. The first series records acquisitions, proposed acquisitions, mergers, and joint ventures for the period of 1944 –1990 in an alphabetical arrangement. The information on these entries is cumulative so that the history of an organization is collected in one place. The second series of notebooks is arranged in chronological blocks. The information is arranged alphabetically by the name of the acquirer. The name of the acquired (merged), type of combination (acquisition, proposed acquisition, joint venture) and the date is also provided. The information is cross-referenced between the two series so that the researcher can approach the information by the name of the parent company or chronologically. Dr. DeSalvo used this resource for many of his publications as well as his master’s thesis. A copy of these publications and his thesis make up the remainder of the collection. Donor Gift of Barbara DeSalvo, 2000 Biography Robert James DeSalvo was born on July 20, 1933 in Toledo, OH. He died on January 23, 1993 in Cincinnati, OH. DeSalvo graduated from high school in Toledo and attended pharmacy school at the University of Toledo where he received his B.S.
    [Show full text]
  • Board of Director Candidates
    2017 Annual General Meeting Board of Director Candidates James I. Healy, M.D., Ph.D. (Current Board Member) James I. Healy, M.D., Ph.D. has served as a member of our board of directors since November 2014. Dr. Healy has been a General Partner of Sofinnova Ventures, a venture capital firm, since June 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories) and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the board of directors of Auris Medical Holding AG, Coherus BioSciences, Inc., Edge Therapeutics, Inc., natera, Inc., ObsEva SA and several private companies. Previously, he served as a board member of Amarin Corporation, Hyperion Therapeutics, Inc., InterMune, Inc., Anthera Pharmaceuticals, Inc., Durata Therapeutics, Inc., CoTherix, Inc., Movetis NV and several private companies. Dr. Healy is currently a Director on the Board of the National Venture Capital Association (NVCA) and the Board of the Biotechnology Industry Organization (BIO). In 2011, Dr. Healy won the IBF Risk Innovator Award and was named as one of the industry’s top leading Life Science investors in 2013 by Forbes Magazine. Dr. Healy holds an M.D. and a Ph.D. in Immunology from Stanford University School of Medicine and holds a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from the University of California, Berkeley. Jan Møller Mikkelsen (Current Board Member) Jan Møller Mikkelsen founded Ascendis Pharma and has served as our President and Chief Executive Officer and as a member of our board of directors since December 2007.
    [Show full text]
  • American Foundation for Pharmaceutical Education Box: 8
    Ronald Reagan Presidential Library Digital Library Collections This is a PDF of a folder from our textual collections. Collection: Turner, Carlton E.: Files Folder Title: American Foundation for Pharmaceutical Education Box: 8 To see more digitized collections visit: https://reaganlibrary.gov/archives/digital-library To see all Ronald Reagan Presidential Library inventories visit: https://reaganlibrary.gov/document-collection Contact a reference archivist at: [email protected] Citation Guidelines: https://reaganlibrary.gov/citing National Archives Catalogue: https://catalog.archives.gov/ .. i ! f;c~~~ I I ,J I American Foundation For Pharmaceutical Education I OIRECTOF)S RADBURN PLAZA BUILDING 14-25 PLAZA ROAD, FAIR LAWN, N.J. 07410 Ronald J. Brenner. Ph.D. (201) 791-5192 INCORPORATED 1942 Cytogen Corpnr~lion William H. Campbell. Ph .D. March 3, 1986 Unfrersity of Washington Herbert 5. Carlin OFFICERS The New York Hospital Peter G. Tombros. Chaimratt of Board Paul N. Clark Abbott Wboralories Ronald J. Brenner. Ph.D .. Via Clwimum of Board L. Jack R. Cole. Ph.D. Robert Hanson, Treasurer William F. Weigel. Coumel and S(•aetary Uni\·ersity of Ariwna Thomas M. Collins Carlton E. Turner, Ph.D. E. PresitJ,,,u SmithK/i11e Beckman Corpora/ion Richard Faust. Ph.D .. Herbert J. Conrad Deputy Assistant to the President Hoffmann-Lo Roche Inc. for Drug Abuse Policy John W. Culligan American Home Products Corporation The White House Angele C. D"Angelo Washington, DC 20001 St. John's University Robert A . Dube Owens-Illinois Dear Carlton, Frederick M. Eckel 1he University of Nonh Carolina George W. Eckelmann Thanks for your kind note just before the holidays ..
    [Show full text]
  • Recovery of Fermentation Products Engineering Foundation Conference Co-Chairs Charles L
    Recovery of Fermentation Products Engineering Foundation Conference Co-chairs Charles L. Cooney, Massachusetts Institute of Technology, USA Kenneth G. Taksen, Pfizer, Inc., USA The Cloister, Sea Island, Georgia, USA 29 January - 3 February, 1984 Sunday, 29 January Tuesday, 31 January Plenary Lectures Purification Methods: Chromatography and Separations Technology: Achilles Heel of the Adsorption Bioprocess Industries Session Chairs E. Gaden, University of Virginia, USA Saxena, Bio Rad Laboratories, USA Innovation in Separations: Key to Success in M. Ladisch, Purdue University, USA Adapting Modern Biology to Industrial Practice Scale-Up Considerations in Process HPLC A. Michaels, USA V Saxena, BioRad Laboratories, USA Purification of Pharmaceutical Compounds by Monday, 30 January Process HPLC W. Skea, Millipore Corp., USA Cell Disruption and Harvesting Scale-up of Affinity Chromatography Session Chairs H. W. Blanch, University of California, USA J. Sinskey, Massachusetts Institute of Technology, USA Protein Recovery from Unclarified Cell Homogenates C.G. Rosen, Alfa Laval, Sweden P. Hedman, Pharmacia Fine Chemicals, Sweden Centrifugal Separation in Biotechnology Selective Recovery of Polar Organics by Solvent A. Larsson, Alfa Laval Separation, Sweden Regenerated Adsorptive Processes Genetic Solutions to Cell Disruption Problems C. J. King, University of California, USA A. J. Sinskey, Massachusetts Institute of Technology, Column Design Factors in Aqueous Liquid USA Chromatography of Fermentation Substrates and Production and Reaction Kinetics of Microbial Cell- Products Lytic Enzyme Systems M. R. Ladisch, Purdue University, USA J. Asenjo, B. A. Andrews and J. B. Hunter, Columbia University, USA Purification Methods: Extraction Mechanical Disruption of Cells Session chair C. Engler, Texas A & M University, USA J. King, University of California, USA Strategy, Tactics and Constraints in Applying Liquid- Purification Methods: Membrane Process Liquid Extraction to the Biotechnology Field Session chair R.
    [Show full text]
  • Europe's Pharmaceutical Industry an Innovation
    EUROPEAN INNOVATION MONITORING SYSTEM (ElMS) ElMS PUBLICATION N° 32 EUROPE'S PHARMACEUTICAL INDUSTRY AN INNOVATION PROFILE BY SPRU, U Diversity of Sussex, UK EUROPEAN COMMISSION DIRECTORATE GENERAL XIII - The Innovation Programme -)( U,j uJ (..) ElMS Project N° 94/114 ... .. ! w THIS STUDY WAS COMMISSIONED BY THE I EUROPEAN COMMISSION, I DIRECTORATE-GENERAL "TELECOMMUNICATIONS, INFORMATION MARKET AND ExPLOITATION OF RESEARCH", UNDER THE INNOVATION PROGRAMME STUDY FINISHED ON: AUGUST96 © 1996, European Commission {'15 b: Ytir/17 I ., Ii • !' .. Contents Page 1 Introduction 1 2 Current Developments in the Pharmaceutical Industry 2 3 Major Market and Technology Trends 12 4 Firm Level Analysis 24 5 Biotechnology - A New Route to Drug Discovery 40 6 Alliances, Linkages and Technology Transfer 49 7 Conclusions 56 REFERENCES 61 Tables: 1: Trends in R&D Intensity of the Pharmaceuticals Sector 4 2: Major Take-overs 1990-1996 8 3: Top Twelve World Market Share with Newly Merged Companies 9 4: Health Expenditure and Pharmaceutical Consumption in Developed Countries 13 5: Pharmaceutical Production in Major World Markets 15 6: R&D Intensity by Industry 18 7: Trends in the Distribution of Pharmaceutical R&D 19 8: Trends in the Distribution of US Patenting in Pharmaceuticals 21 9: Top 50 Branded Products by Country of Origin 23 10: Company Rankings by sales 1993 26 11: Changing Places -the world's top 20 pharmaceutical corporations 1976-94 27 12: Seller Concentration Ratios in the Pharmaceutical Industry 30 13: Top 20 companies in terms of Pharmaceutical R&D expenditures 31 14: Company market share in Europe, United States and Japan 34 15: Geographic Location of Pharmaceutical Firms' US Patenting Activities 37 16: Top Non-national firms patenting in Europe 38 17: Top Ten Biotechnology drugs on the Market in 1993 48 18: Alliances and Joint Ventures between US DBFs and leading European multinationals 50 19a: US-DBFs involved in biotechnology alliances 1982-91 '' .
    [Show full text]
  • Federal Trade Commission Volume Decision 102 (July
    " " " " " " " " 395 CA)mplaint IN THE MATTER OF STERLING DRUG, INC., ET AL. FINAL ORDER, OPINION, ETC. , IN REGARD TO ALLEGED VIOLATION OF SECS. 5 AND 12 OF THE FEDERAL TRADE COMMISSION ACT Docket 8919. Complaint, Feb. 1973-Final Order, July , 1983 This order requires a New Yark City manufacturer of nonprescription drug products, among other things, to cease advertising that "Bayer Aspirin Bayer Children Aspirin Vanquish Cope Midol" or any other nonprescription internal analgesic has been proven to be superior to other pain relieving products, unless such claim has been substantiated by two well-controlled clinical tests. The compa- ny must have a reasonable basis to support any claim that its pain relievers are therapeutically superior to others , as well as competent and reliable scientific evidence for representations that the comparative pharmaceutical qualities of its analgesics have been proven or established. The order further prohibits the manu- facturer from advertising that its products contain any unusual or special ingredi- ent, when in fact such ingredient is commonly used in similar products; or from making any claim which misrepresents the product' s analgesic ingredient. Appearances For the Commission: Joel N Brewer, Randell C. Ogg, Teresa A. Hennessy, Leslie E. Rossen and Roberta Grass. For the respondents: Lionel Kestenbaum, Norman G. Knopf, Wil. liam D. Appler, Jeffrey L. Kestler, Amanda B. Pedersen and Susan S. Pecara, Bergson, Borkland, Margolis Adler Washington, D. COMPLAINT Pursuant to the provisions of the Federal Trade Commission Act and by virtue of the authority vested in it by said Act, the Federal Trade Commission, having reason to believe that Sterling Drug, Inc.
    [Show full text]